IBEX trades 27.8% above Wall Street's consensus target of $24.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IBEX achieves its forward estimates and maintains a stable P/E multiple of 9.4x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, IBEX Limited (IBEX) has a Wall Street consensus price target of $24.00, based on estimates from 6 covering analysts. With the stock currently trading at $33.23, this represents a potential downside of -27.8%. The company has a market capitalization of $448M.
Analyst price targets range from a low of $20.00 to a high of $29.00, representing a 38% spread in expectations. The median target of $23.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, IBEX trades at a trailing P/E of 14.1x and forward P/E of 9.4x. The forward PEG ratio of 0.24 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +11.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $49.74, with bear and bull scenarios of $31.33 and $65.53 respectively. Model confidence stands at 57/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
TTECTTEC Holdings, Inc. | $101M | $2.08 | $34.17 | +1542.8% | Hold | 1.8x | 14 |
CNXCConcentrix Corporation | $1.4B | $22.85 | $35.00 | +53.2% | Buy | 2.1x | 9 |
TASKTaskUs, Inc. | $454M | $5.03 | $10.50 | +108.7% | Buy | 3.8x | 11 |
TLYSTilly's, Inc. | $128M | $4.25 | $5.50 | +29.4% | Hold | — | 17 |
EPAMEPAM Systems, Inc. | $4.7B | $89.55 | $144.63 | +61.5% | Buy | 6.9x | 37 |
CTSHCognizant Technology Solutions Corporation | $20.8B | $43.94 | $76.46 | +74.0% | Hold | 7.7x | 51 |
PEGAPegasystems Inc. | $5.4B | $32.21 | $56.60 | +75.7% | Buy | 11.8x | 23 |
CRMSalesforce, Inc. | $138.8B | $169.52 | $265.75 | +56.8% | Buy | 14.4x | 97 |
NICENICE Ltd. | $6.0B | $98.63 | $118.80 | +20.5% | Buy | 8.9x | 23 |
FIVNFive9, Inc. | $1.9B | $24.98 | $23.00 | -7.9% | Buy | 7.7x | 41 |
Quick answers to the most common questions about buying IBEX stock.
IBEX's consensus price target is $24, -27.8% below the current price of $33.23. The 6 analysts tracking IBEX see downside risk at present valuations.
IBEX has a consensus rating of "Hold" based on 6 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $24 implies -27.8% downside from current levels.
With a forward P/E of 9.4403x, IBEX trades at a relatively low valuation. The consensus target of $24 implies -27.8% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $29 for IBEX, while the most conservative target is $20. The consensus of $24 represents the median expectation. Our quantitative valuation model projects a bull case target of $66 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
IBEX is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IBEX stock forecast based on 6 Wall Street analysts shows a consensus price target of $24, with estimates ranging from $20 (bear case) to $29 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $50, with bear/bull scenarios of $31/$66.
Our quantitative valuation model calculates IBEX's fair value at $50 (base case), with a bear case of $31 and bull case of $66. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 57/100.
IBEX trades at a forward P/E ratio of 9.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 14.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on IBEX, with 0 Sell ratings and a price target of $24 (-27.8% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IBEX analyst price targets range from $20 to $29, a 38% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $24 consensus represents the middle ground. Our model's $31-$66 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.